Orchard Therapeutics (NASDAQ:ORTX)'s stock had its "overweight" rating reiterated by investment analysts at JPMorgan Chase & Co. in a report issued on Monday, Benzinga reports. They presently have a $15.00 target price on the stock, up from their prior target price of $14.00. JPMorgan Chase & Co.'s target price points to a potential upside of 121.89% from the stock's current price.
Several other research firms also recently commented on ORTX. Stifel Nicolaus began coverage on shares of Orchard Therapeutics in a research note on Monday, March 1st. They set a "buy" rating and a $12.00 price target on the stock. Zacks Investment Research downgraded shares of Orchard Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Cantor Fitzgerald assumed coverage on shares of Orchard Therapeutics in a research note on Wednesday, January 6th. They set an "overweight" rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of "Buy" and an average target price of $13.55.
ORTX stock opened at $6.76 on Monday. Orchard Therapeutics has a 12 month low of $3.76 and a 12 month high of $12.38. The firm has a market capitalization of $657.50 million, a P/E ratio of -4.10 and a beta of 1.31. The company has a current ratio of 5.74, a quick ratio of 5.74 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average of $7.07 and a 200-day moving average of $5.39.
Orchard Therapeutics (NASDAQ:ORTX) last posted its quarterly earnings results on Monday, March 1st. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). Sell-side analysts predict that Orchard Therapeutics will post -1.47 EPS for the current year.
In related news, insider Fmr Llc sold 2,045,510 shares of Orchard Therapeutics stock in a transaction on Friday, February 5th. The shares were sold at an average price of $6.98, for a total value of $14,277,659.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.20% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of ORTX. Matisse Capital purchased a new position in Orchard Therapeutics during the 3rd quarter valued at $58,000. California Public Employees Retirement System increased its position in Orchard Therapeutics by 2.6% during the 3rd quarter. California Public Employees Retirement System now owns 176,400 shares of the company's stock valued at $725,000 after purchasing an additional 4,500 shares during the period. Forefront Analytics LLC increased its position in Orchard Therapeutics by 58.8% during the 3rd quarter. Forefront Analytics LLC now owns 30,369 shares of the company's stock valued at $123,000 after purchasing an additional 11,239 shares during the period. JPMorgan Chase & Co. increased its position in Orchard Therapeutics by 61.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,829,662 shares of the company's stock valued at $11,827,000 after purchasing an additional 1,080,805 shares during the period. Finally, Platinum Investment Management Ltd. increased its position in Orchard Therapeutics by 15.4% during the 3rd quarter. Platinum Investment Management Ltd. now owns 411,977 shares of the company's stock valued at $1,693,000 after purchasing an additional 54,957 shares during the period. 66.55% of the stock is currently owned by institutional investors and hedge funds.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Featured Article: How to calculate the annual rate of depreciation
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Stock Selection - What is cash flow?
7 Sports Betting Stocks That Will Shine Beyond March Madness
One of the many consequences of the novel coronavirus was the shutdown of live sports. For sports-minded individuals, one of the events that were missed the most was the NCAA Basketball Tournament affectionately known as March Madness.
But in addition to missing the entertainment that sports provide, cities and states realized, if they didn’t already, that sports are an economic necessity.
Live sports may also be a key to their post-pandemic future. But this goes beyond hotels and restaurants.
Sports betting has become big business. Currently, 25 states and the District of Columbia have legalized sports betting either by statute or by ballot initiative. That list is likely to grow. Many states face budget deficits and want to legalize sports betting for the revenue that it could receive.
And this is about more than allowing gamblers to place bets via a sportsbook in a casino. The real driver for this is mobile sports betting. According to the American Gaming Association, over 47 million people are expected to place bets during the NCAA basketball tournament, with approximately one-third of those bets (17.8 million) being placed online.
To help you take advantage of this still-emerging trend, we’ve put together this special presentation. Here we’ll highlight seven sports betting stocks that should generate significant revenue during March Madness and beyond.
View the "7 Sports Betting Stocks That Will Shine Beyond March Madness"